Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 9/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 6/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.44 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.43 |
| ▸ | GRIA4 | P48058 | 4/20 | 0.42 |
| ▸ | GRIK3 | Q13003 | 4/20 | 0.42 |
| ▸ | GRIK5 | Q16478 | 4/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Serine SCHEMBL5338147 | 1.00 | GRIK1 (0.50) | GRIK1SLC1A1SLC7A5GRIK2PTGS1 | |
| Serine SCHEMBL18427841 | 0.93 | SLC7A5 (0.46) | GRIK1SLC1A1SLC7A5GRIK2PTGS1 | |
| Serine SCHEMBL18427842 | 0.93 | SLC7A5 (0.46) | GRIK1SLC1A1SLC7A5GRIK2PTGS1 | |
| Serine SCHEMBL2166438 | 0.90 | SLC1A1 (0.52) | GRIK1SLC1A1SLC7A5GRIK2PTGS1 | |
| Serine SCHEMBL2509471 | 0.90 | SLC1A1 (0.52) | GRIK1SLC1A1SLC7A5GRIK2PTGS1 | |
| Serine SCHEMBL2166436 | 0.90 | SLC1A1 (0.52) | GRIK1SLC1A1SLC7A5GRIK2PTGS1 | |
| Aspartic Acid SCHEMBL8671844 | 0.89 | GRIK1 (0.52) | GRIK1SLC1A1SLC7A5GRIK2GRM1 | |
| Aspartic Acid SCHEMBL8671842 | 0.89 | GRIK1 (0.52) | GRIK1SLC1A1SLC7A5GRIK2GRM1 | |
| Serine SCHEMBL29013386 | 0.87 | SLC1A1 (0.50) | GRIK1SLC1A1SLC7A5GRIK2PTGS1 | |
| Serine SCHEMBL28227342 | 0.87 | SLC1A1 (0.50) | GRIK1SLC1A1SLC7A5GRIK2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518989-B2 | Prodrugs of short-chain fatty acids and treatment methods | GEORGIA HEALTH SCIENCES UNIVERSITY RESEARCH INSTITUTE, INC. (US) | 2013-08-27 | — | — | US | claimed |
| US-20110245339-A1 | PRODRUGS OF SHORT-CHAIN FATTY ACIDS AND TREATMENT METHODS | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC (US) | 2011-10-06 | — | — | US | claimed |
| US-20090123388-A1 | Prodrugs of Short-Chain Fatty Acids and Treatment Methods | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE (US) | 2009-05-14 | — | — | US | claimed |
| WO-2006076734-A2 | PRODRUGS OF SHORT-CHAIN FATTY ACIDS AND TREATMENT METHODS | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE (US) | 2006-07-20 | — | — | WO | claimed |
| US-20230201226-A1 | COMBINATION THERAPY FOR REDUCING DRUG-INDUCED NEPHROTOXICITY, DYSLIPIDEMIA AND HYPERGLYCEMIA | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-06-29 | — | — | US | disclosed |
| EP-3426766-B1 | METHOD FOR CONTINUOUS BIOSENSING | YISSUM RESEARCH AND DEVELOPMENT COMPANY OF THE HEBREW UNIV OF JERUSALEM LTD (IL) | 2022-12-28 | — | — | EP | disclosed |
| US-20210379094-A1 | METHOD FOR REDUCING DRUG-INDUCED NEPHROTOXICITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2021-12-09 | — | — | US | disclosed |
| US-20190086391-A1 | METHOD AND SYSTEM FOR CONTINUOUS BIOSENSING | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2019-03-21 | — | — | US | disclosed |
| EP-3426766-A1 | METHOD AND SYSTEM FOR CONTINUOUS BIOSENSING | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017153992-A1 | METHOD AND SYSTEM FOR CONTINUOUS BIOSENSING | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2017-09-14 | — | — | WO | disclosed |
| US-8518989-B2 | Prodrugs of short-chain fatty acids and treatment methods | GEORGIA HEALTH SCIENCES UNIVERSITY RESEARCH INSTITUTE, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2434421-A2 | Compositions and methods for modeling saccharomyces cerevisiae metabolism | The Regents of The University of California (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20110245339-A1 | PRODRUGS OF SHORT-CHAIN FATTY ACIDS AND TREATMENT METHODS | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110158980-A1 | METHODS TO TREAT AND SCREEN FOR AGENTS TO TREAT OBESITY | TRUSTEES OF TUFTS COLLEGE (US) | 2011-06-30 | — | — | US | disclosed |
| WO-2010019434-A1 | METHODS TO TREAT AND SCREEN FOR AGENTS TO TREAT OBESITY | TRUSTEES OF TUFTS COLLEGE (US) | 2010-02-18 | — | — | WO | disclosed |
| US-20090123388-A1 | Prodrugs of Short-Chain Fatty Acids and Treatment Methods | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE (US) | 2009-05-14 | — | — | US | disclosed |
| WO-2006076734-A2 | PRODRUGS OF SHORT-CHAIN FATTY ACIDS AND TREATMENT METHODS | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090123388-A1 | Prodrugs of Short-Chain Fatty Acids and Treatment Methods | SLC1A5, SPTSSB, SLC27A1 | GRIK1 1958/4885SLC1A1 45/4885SLC7A5 5/4885 |
| US-20110245339-A1 | PRODRUGS OF SHORT-CHAIN FATTY ACIDS AND TREATMENT METHODS | SLC1A5, SPTSSB, SLC27A1 | GRIK1 1958/4885SLC1A1 45/4885SLC7A5 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.